Ultragenyx Pharmaceutical (RARE) Minority Interest (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 4 years of Minority Interest data on file, last reported at $7.0 million in Q1 2026.

• On a quarterly basis, Minority Interest changed 0.0% year-over-year to $7.0 million in Q1 2026; TTM through Mar 2026 was $7.0 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $7.0 million, changed 0.0% from the prior year.
• Minority Interest for Q1 2026 stood at $7.0 million, roughly flat from $7.0 million in the prior quarter.
• Over the last five years, Minority Interest for RARE reached as high as $7.0 million in Q3 2024 and fell as low as $7.0 million in Q3 2024.
• Historically, Minority Interest has averaged $7.0 million across 3 years, with a median of $7.0 million in 2024.
• On a YoY basis, Minority Interest climbed as much as 0.0% in 2025 and fell as far as 0.0% in 2025.
• Year by year, Minority Interest stood at $7.0 million in 2024, then changed by 0.0% to $7.0 million in 2025, then changed by 0.0% to $7.0 million in 2026.
• Per Business Quant data, the three most recent Minority Interest figures were $7.0 million in Q1 2026, $7.0 million in Q4 2025, and $7.0 million in Q3 2025.